panitumumab

Known as: panitumumab [Chemical/Ingredient], ABX-EGF, Clone E7.6.3, panitumumab antibody, human 
A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND The Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE To evaluate panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression… (More)
Is this relevant?
Review
2010
Review
2010
Personalized cancer medicine based on the genetic milieu of individual colorectal tumors has long been postulated, but until… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE In a previous cohort study, we proposed that responsiveness of metastatic colorectal cancer (mCRC) to anti-epidermal… (More)
Is this relevant?